Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FormidableMD vs REMEVi

FormidableMD
Graded #71

Lower grade

vs+0.29999999999999716
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 73.2/100, but only just.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated. FormidableMD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +1
56
57
Dose & formulationREMEVi +5
78
83
Clinical oversightFormidableMD +2
88
86
Labs & monitoringFormidableMD +28
83
55
FulfillmentREMEVi +25
72
97
Contract termsREMEVi +8
61
69
FormidableMD · left barREMEVi · right bar

The numbers

MetricFormidableMDREMEVi
WeighScore73.2/10073.5/100
GradeCC
Scorecard rank#71#70
Semaglutide$169/mo (1 mg dose, compounded)$219/mo
Tirzepatide$199/mo (10 mg dose, compounded)$319/mo
Coverage1 stateAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
FormidableMD

Graded #71 · C

Strengths

  • Transparent, published dose-by-dose pricing for semaglutide ($169-$269/mo) and tirzepatide ($199-$319/mo) with no membership or commitment
  • Offers both FDA-approved and compounded GLP-1s (plus oral options) from 503A pharmacies, with a real provider at every visit
  • Boutique physician-led model bundling labs, peptides, HRT/TRT and urgent care; FSA/HSA eligible

Where it loses points

  • Florida-focused telehealth — availability outside FL is not advertised, so out-of-state access is uncertain
  • Medication cost is on top of a $199 initial consultation and $99 follow-up visits (pay-per-visit, not an all-in monthly price)
  • The 503A compounding pharmacy partner is not named on the site
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard